EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploring CAR T-Cell Dynamics: Balancing Potent Cytotoxicity and Controlled Inflammation in CAR T-Cells Derived from Systemic Sclerosis and Myositis Patients

Janin Dingfelder iD, Jule Taubmann, Franziska von Heydebrand, Michael Aigner, Christina Bergmann, Johannes Knitza iD, Soo Park, Joseph K Cheng, Thomas Van Blarcom, Georg Schett, Andreas Mackensen, Gloria Lutzny-Geier iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26020467 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Janin Dingfelder und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, 9105…. Hauptthemen laut MEDLINE: Scleroderma, Systemic, Myositis, Receptors, Chimeric Antigen, Immunotherapy, Adoptive. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kyverna Therapeutics, Leibniz Award, Lupus Insight prize from the Lupus Research Alliance, Kyverna Therapeutics, Lupus Research Alliance.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and idiopathic inflammatory myositis (IIM) are autoimmune diseases managed with long-term immunosuppressive therapies. Hu19-CD828Z, a fully human anti-CD19 chimeric antigen receptor (CAR) with a CD28 costimulatory domain, is engineered to potently deplete B-cells. In this study, we manufactured Hu19-CD828Z CAR T-cells from peripheral blood of SLE, IIM, and SSc patients and healthy donors (HDs). CAR-mediated, CD19-specific activity of these cells was evaluated in vitro by assessing cytotoxicity, cytokine release, and proliferation assays in response to autologous CD19+ B-cells, the CD19+ NALM-6 B-cell line, or a CD19− U937 non-B-cell line as targets. The results demonstrated an increased proliferation of Hu19-CD828Z CAR T-cells and dose-dependent cytotoxicity against primary autologous and NALM-6 B-cells compared to non-transduced controls or co-cultures with non-B-cells. Notably, autoimmune-patient-derived CAR T-cells produced lower levels of inflammatory cytokines than healthy-donor-derived CAR T-cells in response to CD19+ B-cell targets. These data support the potential of Hu19-CD828Z and its therapeutic cell product KYV-101 as a therapeutic strategy to achieve deep B-cell depletion in SLE, IIM, and SSc patients, and highlights its promise for broader application in B-cell-driven autoimmune disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Scleroderma, SystemicMyositisReceptors, Chimeric AntigenImmunotherapy, AdoptiveT-LymphocytesHumansAntigens, CD19B-LymphocytesCytokinesInflammationFemaleCell ProliferationMiddle AgedMaleAdultCytotoxicity, Immunologic

Stichwörter der Autor:innen

T-cellsautoimmune diseaseschimeric antigen receptorcytokinesidiopathic inflammatory myositissystemic lupus erythematosussystemic sclerosis

Substanzen

Antigens, CD19Receptors, Chimeric AntigenCytokines

Autor:innen und Institutionen

  • Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany.
  • Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany.
  • Bavarian Cancer Research Center (BZKF), 91054 Erlangen, Germany.
  • Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany.
  • Institute for Digital Medicine, University Hospital Giessen-Marburg, Philipps University Marburg, 35043 Marburg, Germany.
  • Kyverna Therapeutics, Emeryville, CA 94608, USA.

ORCID-Profile: Janin Dingfelder, Johannes Knitza, Gloria Lutzny-Geier

Förderung

  • Kyverna Therapeutics, Leibniz Award, Lupus Insight prize from the Lupus Research Alliance
  • Kyverna Therapeutics
  • Lupus Research Alliance

Zitieren

APA

Dingfelder, J., Taubmann, J., von Heydebrand, F., Aigner, M., Bergmann, C., Knitza, J., Park, S., Cheng, J. K., Van Blarcom, T., Schett, G., Mackensen, A., & Lutzny-Geier, G. (2025). Exploring CAR T-Cell Dynamics: Balancing Potent Cytotoxicity and Controlled Inflammation in CAR T-Cells Derived from Systemic Sclerosis and Myositis Patients. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26020467

Vancouver

Dingfelder J, Taubmann J, von Heydebrand F, Aigner M, Bergmann C, Knitza J, et al. Exploring CAR T-Cell Dynamics: Balancing Potent Cytotoxicity and Controlled Inflammation in CAR T-Cells Derived from Systemic Sclerosis and Myositis Patients. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26020467

BibTeX
@article{Dingfelder2025,
  author = {Dingfelder, Janin and Taubmann, Jule and von Heydebrand, Franziska and Aigner, Michael and Bergmann, Christina and Knitza, Johannes and Park, Soo and Cheng, Joseph K and Van Blarcom, Thomas and Schett, Georg and Mackensen, Andreas and Lutzny-Geier, Gloria},
  title = {Exploring CAR T-Cell Dynamics: Balancing Potent Cytotoxicity and Controlled Inflammation in CAR T-Cells Derived from Systemic Sclerosis and Myositis Patients},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26020467}
}
Kostenlos starten →